Navigation Links
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
Date:4/24/2013

SUNNYVALE, Calif., April 24, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will report financial results and recent developments for its three months ended March 31, 2013 after the NASDAQ Market closes on Wednesday, May 1, 2013.  The Company will conduct a conference call and audio webcast at 4:30 p.m ET on the same day. As previously announced, the Company changed its fiscal year end from June 30 to December 31, effective December 31, 2012. As a result, the three months ended March 31, 2013 represents the Company's fiscal 2013 first quarter.

Conference call and webcast details:

Date: May 1, 2013
Time: 4:30 PM ET
Listen via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free: (877)-407-0778
International: (201)-689-8565

Replay Number (Toll Free): (877)-660-6853
Replay Number (International): (201)-612-7415
Conference ID #: 413317

A webcast replay will be available on the Pharmacyclics website for 30 days.

About Pharmacyclics
Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medical healthcare needs; and to identify promising product candidates based on scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently, Pharmacyclics has three product candidates in clinical development and several preclinical molecules in lead optimization. The Company is committed to high standards of ethics, scientific rigor, and operational efficiency as it moves each of these programs to viable commercialization.
The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
2. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
3. Pharmacyclics, Inc. Prices Public Offering of Common Stock
4. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
5. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
6. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
7. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
8. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
9. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
10. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
11. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 FinancialBuzz.com News Commentary   ... Medical cannabis products around the world ... projects that the global medical cannabis market will reach a value of ... a major market for the new growing industry. By the end of ... buy and sell medical cannabis. More conservative states like Arkansas ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, ... growing market of deep learning solutions within the healthcare domain. Primarily ... as a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... 2017 Global Ampoules Market report ... classifications, applications and industry chain structure. The Ampoules market ... history, competitive landscape analysis, and major regions, development status. ... ... pages providing 10 company profiles and 183 tables and ...
Breaking Medicine Technology:
(Date:3/24/2017)... Sedona, Arizona (PRWEB) , ... March 24, 2017 ... ... Shamangelic Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Jorge Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... are now offering treatments for sleep apnea and TMJ at their office. TMJ, ... apnea , specifically the obstructive type, is increasingly being treated at dental offices ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate ... historical facts, cultural practices, goods, services, and societal issues tend to appreciate and love ... the popular practice of utilizing running events for causes around the world. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner of ... Frederick, MD. Judy says, “I am passionate about sharing Reiki as a holistic, ... difficult and challenging time.” , A Certified Medical Reiki™ Master trained by Raven ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
Breaking Medicine News(10 mins):